The estimated Net Worth of Walid Abi Saab is at least 637 千$ dollars as of 26 June 2024. Walid Saab owns over 1,447 units of uniQure N.V stock worth over 630,434$ and over the last few years Walid sold QURE stock worth over 6,309$.
Sign up
Walid Saab QURE stock SEC Form 4 insiders trading
Walid has made over 1 trades of the uniQure N.V stock since 2024, according to the Form 4 filled with the SEC. Most recently Walid sold 1,447 units of QURE stock worth 6,309$ on 26 June 2024.
The largest trade Walid's ever made was selling 1,447 units of uniQure N.V stock on 26 June 2024 worth over 6,309$. On average, Walid trades about 724 units every 0 days since 2024. As of 26 June 2024 Walid still owns at least 115,253 units of uniQure N.V stock.
You can see the complete history of Walid Saab stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Walid Saab's mailing address?
Walid's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Insiders trading at uniQure N.V
Over the last 8 years, insiders at uniQure N.V have traded over 35,572,573$ worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van、Paula Soteropoulos、William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of 37,634$. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth 6,309$.
What does uniQure N.V do?
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
What does uniQure N.V's logo look like?
Complete history of Walid Saab stock trades at uniQure N.V
uniQure N.V executives and stock owners
uniQure N.V executives and other stock owners filed with the SEC include:
-
Matthew Kapusta,
Chief Executive Officer, Chief Financial Officer, Executive Director -
Robert Gut,
Executive Director -
Alexander Kuta,
Executive Vice President, Operations -
Maria Cantor,
Senior Vice President, Investor Relations and Communications -
Matthew Craig Kapusta,
CEO & Exec. Director -
Dr. Alexander E. Kuta Ph.D.,
Exec. VP of Quality & Regulatory -
Dr. Ricardo Dolmetsch Ph.D.,
Pres of R&D -
Christian Klemt,
CFO, Principal Financial Officer & GM of Amsterdam Site -
David Meek,
Non-Executive Independent Director -
Philip Astley-Sparke,
Independent Non-Executive Chairman of the Board -
Jack Kaye,
Non-Executive Independent Director -
Jeremy Springhorn,
Non-Executive Independent Director -
Madhavan Balachandran,
Non-Executive Independent Director -
Paula Soteropoulos,
Non-Executive Independent Director -
Leonard Post,
Director -
Ricardo Dolmetsch,
President, Research and Development -
Erin Boyer,
Chief People & Culture Office -
Richard Porter Ph.D.,
SVP of R&D and GM of Corlieve -
Dr. Tamara Tugal Ph.D., MBA,
Bus. Devel. Director -
Maria E. Cantor,
Chief Communications Officer -
David Cerveny,
Chief Legal Officer, Gen. Counsel & Sec. -
Pierre Caloz,
Chief Operating Officer -
Prof. Hugo Katus,
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany -
Rachelle Suzanne Jacques,
Director -
Christian Meyer,
Chief Medical Officer -
Harald Petry,
Chief Scientific Officer -
Maiken Keson Brookes,
General Counsel -
Jonathan Garen,
Chief Business Officer -
David Schaffer,
Director -
Paul E Firuta,
Chief Commercial Officer -
William Lewis,
Director -
Steven Zelenkofske,
Chief Medical Officer -
Deventer Sander Van,
EVP, Research & Product Dev. -
Scott T. Mc Millan,
Chief Operating Officer -
Pierre Caloz,
Chief Operating Officer -
Christian Klemt,
Chief Financial Officer -
Jeannette Potts,
Chief Legal Officer -
Walid Abi Saab,
Chief Medical Officer